Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection

An Open-label, Sequential Parallel Group, Single Ascending Dose Following Intravenous Bolus/Infusion Administration in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MT1002 for Injection

This is an open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of MT1002 for injection following intravenous bolus/infusion ascending dose administration.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: MT1002 for injection

Detailed Description

An initial, single dose escalation study of MT1002 for injection for injection in heathy subjects will be performed to evaluate safety, pharmacokinetics, and pharmacodynamics after intravenous bolus and infusion administration.

A total of 36 subjects (6 subjects per cohort) in 6 dose levels . At each dose level, a single sentinel subject will be dosed first. Sentinel subjects will receive a phone call at 48 hours ±4 hours to inquire about their status. If no dose-limiting toxicity is observed for 48 hours post-dose, the remaining 5 subjects in that dose level will be treated.

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Maryland
    • Baltimore, Maryland, United States, 21201
      • Pharmaron CPC, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female aged 18-60 years.
2. Able and willing to give written informed consent.
3. BMI between 18.0 and 34.0 kg/m2, inclusive.
4. Subjects must be able to refrain from consuming xanthine, quinine and caffeine containing beverages, and must refrain from prolonged intensive physical exercise during the study (from 72 hours prior to dosing until the last study visit).

5. Women must be:

   • not pregnant
   • not breast-feeding
   • not planning to become pregnant during the study
6. All females must have a negative serum pregnancy test at screening and a negative urine pregnancy test at check-in on Day -1. All women must agree to use an adequate method of contraception during the study and for 30 days following the end-of-study visit.
7. Male subjects must agree to utilize a highly effective method of contraception (condom plus spermicide) during heterosexual intercourse from clinic admission until 30 days following the end of study visit.
8. Male subjects must agree to refrain from sperm donation from clinic admission until at least 30 days following the end of study visit.

Exclusion Criteria:

1. Any medical condition, clinical laboratory test or other reason which in the judgment of the Investigator or designee makes the subject unsuitable for the study.
2. Does not tolerate venepuncture or has poor venous access that would cause difficulty for collecting blood samples.
3. Has participated in an investigational drug study and received investigational drug within 30 days or 5 half-lives (whichever is longer) prior to the screening visit or who is currently participating in another clinical trial.
4. Has experienced an acute illness within 14 days prior to the screening visit.
5. Any clinically significant abnormalities in hematology, blood chemistry and/or urinalysis lab tests at screening or at D1.
6. Known hypersensitivity to MT1002

8. History of any drug hypersensitivity that would require urgent medical care 9. Use of aspirin or any non-steroidal anti-inflammatory drug within 14 days of Day -1 10. Any serum FSH result <40mIU/mL 11. History, symptoms, or signs of cardiovascular or cerebrovascular disease. 12. History, symptoms, or signs of severe hepatic impairment. 13. HbA1c >5.7% at Screening 14. History of excessive bleeding from an injury or after surgery or dental work.

15. History of heavy or long menstrual bleeding. 16. History of blood in urine or stool or history of black stools. 17. History of easy bruising. 18. PT or aPTT > upper limit of normal at Screening or Day -1. 19. Platelet count < lower limit of normal at Screening or Day -1 20. History within the previous 3 years or current evidence of abuse of any drug, prescription or illicit, or alcohol; a positive urine screen for drugs of abuse or breathalyzer alcohol test.

21. Positive urinary test for drugs of abuse and/or alcohol breath test at Screening and/or at check-in on Day -1.

22. Supine systolic blood pressure (BP) > 130 mm Hg, diastolic BP > 80 mm Hg, respiratory rate >20 breaths per minute, pulse >90 beats per minute, or temperature >37.5º at Screening.

23. Abnormal 12-lead ECG that may jeopardize the subject's safety to participate in this study or a screening 12-lead ECG demonstrating any one of the following: heart rate (HR) > 100 beats per minute (bpm), QRS > 120 milliseconds (msec), QTcF > 450 msec, or PR > 220 msec.

24. Electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, or other medicinal products that lead to QT prolongation.

25. Any clinically significant alanine aminotransferase (ALT), alkaline phosphatase (AP), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) or bilirubin abnormalities judged by the Investigator or designee at Screening.

27. Tobacco or nicotine users except subjects who stopped using tobacco or nicotine 90 days or more before signing the informed consent.

28. Positive Hepatitis C antibody, Hepatitis B surface antigen, or positive human immunodeficiency virus (HIV) antibody.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SEQUENTIAL
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: MT1002 for Injection; Single Ascending Dose following Intravenous Bolus/Infusion Administration in Healthy Subjects	Drug: MT1002 for injection; Study drug will be administered by an intravenous bolus dose followed by an infusion of 4 hours.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum observed concentration (Cmax)	Maximum observed concentration following intravenous bolus/infusion administration of MT1002 for injection	24 hours
Time to maximum concentration (Tmax)	Time to maximum concentration (Tmax)	24 hours
Area under the concentration-time curve (AUC) from Hour 0 to the last measurable concentration (AUC0-last)	Area under the concentration-time curve (AUC) from Hour 0 to the last measurable concentration (AUC0-last)	24 hours
AUC extrapolated to infinity (AUC0-∞)	AUC extrapolated to infinity (AUC0-∞)	24 hours
Activated clotting time (ACT)	Activated clotting time (ACT)	24 hours
Activated partial thromboplastin time (aPTT)	Activated partial thromboplastin time (aPTT)	24 hours
International normalized ratio (INR)	International normalized ratio (INR)	24 hours

Collaborators and Investigators

• Sponsor: Shaanxi Micot Technology Limited Company
• Investigators: Principal Investigator: Mohamed Al-Ibrahim, MB, Pharmaron CPC, Inc.

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 29, 2019
• Primary Completion (ACTUAL): August 1, 2019
• Study Completion (ACTUAL): November 27, 2019

Study Registration Dates

• First Submitted: September 26, 2019
• First Submitted That Met QC Criteria: October 3, 2019
• First Posted (ACTUAL): October 7, 2019

Study Record Updates

• Last Update Posted (ACTUAL): July 29, 2022
• Last Update Submitted That Met QC Criteria: July 28, 2022
• Last Verified: September 1, 2019

More Information

Terms related to this study

• Other Study ID Numbers: MT1002-Ⅰ-C01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No